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Abstract 
Aims: Parkinson's disease (PD) has the second highest incidence among neurodegenerative 
diseases in the world population. The study aimed to investigate the presence of some 
cardiovascular risk factors – dyslipidemia, diabetes, and hypertension – in PD patients and to 
compare their risk with non-PD population in South East Hungary. 
Methods: A case-control study was conducted at the Department of Neurology, University of 
Szeged, Hungary. The study included 1299 subjects out of which 620 patients were identified as 
cases of diagnosed PD and 679 as controls. Logistic regression analyses were conducted to reveal 
the association of vascular risk factors with PD. 
Results: In the univariate analysis, diabetes mellitus was positively associated with PD, while 
dyslipidemia showed negative association to it in the total population, and no significant 
associations were found between hypertension and PD. The multivariate logistic regression models 
showed that the odds of diabetes mellitus was higher (OR=2.86), while the odds of dyslipidemia 
was lower (OR=0.58) among PD patients than in the control group. Hypertension showed a 
different pattern by gender: the odds of registered hypertension was significantly lower in female 
PD patients (OR=0.68), whereas the result was not significant in males. 
Conclusions: This is the first study that provides a comprehensive view of the cardiovascular risk 
factors in PD patients in Hungary and shows considerable relationship between diabetes mellitus 
and PD. 
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Absztrakt 
 
Bevezetés és célkitűzés: A Parkinson-kór (PD) a második leggyakrabban előforduló 
neurodegeneratív kórkép a világon és így hazánkban is. A vizsgálat célja egyes kardiovaszkuláris 
rizikótényezők – lipidanyagcsere-zavarok, diabetes mellitus, magas vérnyomás betegség – 
előfordulásának mérése volt Parkinson-kóros és attól mentes betegek körében. 
Módszer: Az eset-kontroll vizsgálat a Szegedi Tudományegyetem Neurológiai Klinikáján történt. 
A teljes minta 1299 főből állt, amelyből 620 fő volt a diagnosztizált PD beteg, 679 fő pedig a 
kontroll páciens. A vaszkuláris tényezők és a PD összefüggéseit logisztikus regresszióval 
modelleztük.  
Eredmények: Az egyváltozós regressziós elemzés szerint a diabétesz pozitív, a lipidanyagcsere 
zavarai negatív kapcsolatot mutattak a PD-vel, a magas vérnyomás betegség esetében pedig nem 
igazolódott összefüggés. A többváltozós logisztikus regressziós modell megmutatta, hogy a 
diabétesz esélyhányadosa (OR=2.86; p<0.001) szignifikánsan nagyobb, míg a lipidanyagcsere 
zavaroké kisebb (OR=0.58; p<0.001) volt a PD betegek körében, mint a kontroll csoportban. A 
magasvérnyomás esélye viszont szignifikánsan kisebb (OR=0.68; p=0.039) volt PD esetén a nők 
körében, míg a férfiaknál ez nem volt megfigyelhető. 
Konklúzió: Ez az első olyan hazai vizsgálat, ami a Parkinson-kórt a kardiovaszkuláris betegségek 
tükrében vizsgálja, és összefüggés mutatkozott a diabétesz és a PD között. 
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Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer's disease, and it affects approximately seven million people globally, and the prevalence 
of the disease rises parallel with the aging of the population 1. Approximately 20 thousand people 
with PD live in Hungary 2. It is also well known that coronary artery diseases are among the leading 
causes of death in the world population as well as in Hungary 3.  
Currently, several epidemiological studies search for how vascular risk factors such as diabetes or 
hypercholesterolemia affect the occurrence of PD. Studies describing the relationship between 
diabetes and PD have shown controversial results. A large multicenter analysis in Germany shows 
that the metabolic control of PD patients is better than that of patients with type 2 diabetes 4, while 
other studies have found positive association between diabetes and the risk of developing PD 5–7. 
A large population-based case-control study in Denmark shows that those who were administered 
an antidiabetic drug was associated with a 35% increased risk for PD 5. These results have been 
confirmed by a biomarker analysis showing that diabetes and PD are strongly linked at the 
molecular level 8. The association between the risk of PD and hypercholesterolemia has been 
described by several studies, but those results are also controversial 9–12. Some studies have found 
an inverse relationship between hypercholesterolemia and the risk of PD 9–11, while a systematic 
review has stated that the results are inconsistent, and further studies are needed 12. Other studies 
have investigated the associations between hypertension and antihypertensive drugs, and the risk 
of PD 13–15. Louis et al. have not found evidence of a protective effect of antihypertensive drugs in 
PD 13, while Ritz et al. have suggested that there is a potential neuroprotective role of centrally 
acting L-type calcium channel blockers of the dihydropyridine class in PD 14. Qui et al. have found 
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that high–normal blood pressure and hypertension are associated with an increased risk of PD in 
women, but there was no significant association identified in men 15. 
Considering that the results of previous epidemiological studies are conflicting, the aim of our 
study was to investigate the prevalence of cardiovascular risk factors (diabetes mellitus, 
dyslipidemia, and hypertension) in PD patients and to compare their risk with non-PD population 
in South East Hungary. 
 
Patients and Methods 
Study Design and Participants 
A classical case-control study was conducted at the Department of Neurology, Albert Szent-
Györgyi Health Center, University of Szeged, Hungary. We gained our data from the computerized 
MedSolution integrated hospital information system between January 1, 2000 and January 1, 2013.  
The total sample consisted of 1299 subjects who were hospitalized during the study period at the 
Department of Neurology, out of which 620 patients were identified as cases and 679 as controls. 
Cases included all hospitalizations in the study period if they had a diagnosis of PD (ICD-10 code: 
G20H0). Controls were matched to cases by age and sex, and they were selected from the patients 
with the diagnosis of epilepsy (ICD-10 code: G40) or back pain (ICD-10 code: M54) of the same 
department. The exclusion criteria for the control group was previous diagnosis of Parkinson‘s or 
Alzheimer’s disease, multiple sclerosis, myasthenia gravis or secondary Parkinsonism.  
Study Variables 
Sex, age, comorbidity of dyslipidemia (ICD-10 code: E78), diabetes (ICD-10 codes: E1–E14), and 
hypertension (ICD-10 codes: I10–I15) of the subjects were collected from the MedSolution 
system. All data were registered anonymously. 
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Statistical Analyses 
Simple descriptive statistics were used to characterize the participants. Chi-square tests were 
applied to compare the basic characteristics of case and control groups. Univariate and multivariate 
logistic regression analyses were conducted to assess the odds of vascular risk factors (diabetes, 
dyslipidemia, and hypertension) in PD. All logistic models were developed for the total population, 
and for males and females, separately. In the regression models, we calculated the odds ratio (OR) 
and the 95% confidence interval (95% CI) for each predictor. Statistical significance was set up at 
p values lower than 0.05. Data analyses were performed using IBM SPSS software version 20. 
Ethics Statement 
The study protocol was approved by the Human Institutional and Regional Biomedical Research 
Ethics Committee, University of Szeged (Registration number: 164/2012). 
 
Results 
The mean age and gender distribution of cases (PD-patients) and controls (non-PD patients) were 
similar (Table 1). Diabetes mellitus was significantly more frequent, whereas dyslipidemia was 
less frequent in the case group than in the control group, but no difference was found related to 
hypertension (Table 1).  
In the univariate logistic regression analyses (Table 2), diabetes mellitus was positively associated 
with PD, i.e., the odds of diabetes mellitus was significantly higher in the PD group than in the 
control group (ORtotal=2.65, 95%CI: 2.05–3.43; ORmale=2.45, 95%CI: 1.74–3.45; ORfemale=2.97, 
95%CI: 2.01–4.40). Dyslipidemia showed negative association; the odds were 0.62 (95%CI: 0.49–
0.79) in the total population, 0.54 (95%CI: 0.38–0.75) in males and 0.71 (95%CI: 0.51–0.99) in 
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females. In the univariate analyses, no significant associations were found between hypertension 
and PD in the total population, and among males and females, respectively. 
Age (years) and vascular predictors were involved in the multivariate logistic regression models 
of the total, the male and the female populations (Table 3). The common analysis of the factors 
showed that the odds of diabetes mellitus was higher (ORtotal=2.86, 95%CI: 2.19–3.73; 
ORmale=2.72, 95%CI: 1.90–3.89; ORfemale=3.24, 95%CI: 2.16–4.84), while the odds of 
dyslipidemia was lower (ORtotal=0.58, 95%CI: 0.46–0.75; ORmale=0.48, 95%CI: 0.33–0.69; 
ORfemale=0.70, 95%CI: 0.50–1.00) among PD patients than in the control group. Hypertension 
showed a different pattern by gender: the odds of registered hypertension was significantly lower 
in female PD patients (ORfemale=0.68, 95%CI: 0.48–0.98), whereas in males the result was not 
significant (ORmale=0.95, 95%CI: 0.69–1.32). 
 
Discussion  
The results of our case-control study showed that diabetes mellitus was positively, while 
dyslipidemia was negatively associated with PD in males and females, whereas hypertension was 
negatively associated with PD only in females. 
The association between diabetes mellitus and PD has been described in several studies 5, 16–18. The 
diagnosis or the ongoing treatment of diabetes has significantly been associated with an increased 
risk of PD in a Danish population-based case-control study 5. Diabetes has been positively 
correlated with the severity of the disease as well (OR=1.5) in a Greek cross-sectional study 16. 
Another case-control study in the USA has also found a significant relationship between PD and 
diabetes mellitus; the results of the study show a difference between the two genders: men with 
diabetes mellitus had a significantly lower risk of PD (OR=0.52) than men without diabetes, 
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whereas the association in women was not significant 17. Nonetheless, a large meta-analysis has 
found negative association with future PD (OR=0.75) and diabetes mellitus 18. Our findings are in 
accordance with the Danish, Greek and USA studies showing a considerable relationship between 
diabetes mellitus and PD. 
The relationship between PD and cause of diabetes mellitus has been studied many times. One 
explanation is the inborn error of the insulin receptor expression in subtantia nigra 19, but oxidative 
stress and mitochondrial disorders were linked to the disease process as well. 
Similarly, studies about the complex problem of elevated lipid levels and PD relationship have 
been published, as well. A large prospective study has described that high dietary intake of 
cholesterol increased the risk of PD 20, while high levels of cholesterol, triglycerides, total lipids 
and mean systolic and diastolic blood pressures have been less frequent in PD patients than in 
controls in a case-control study in Italy 21. The Honolulu–Asia Aging Study has also revealed an 
inverse association between LDL cholesterol and PD risk 22. In another prospective study, PD has 
not been significantly associated with hypertension, high cholesterol level, or diabetes, but it 
modestly declined with the increasing blood cholesterol level 23. The association between blood 
pressure and the risk of PD has also been analyzed in other studies. High blood pressure is 
associated with PD only in females in the National FINRISK Study; the results indicate the 
importance of optimal blood pressure control to reduce the risk of PD 15. The protective effect of 
antihypertensive medications, such as centrally acting L-type calcium channel blockers of the 
dihydropyridine class in PD have been described by Ritz et al. 14.  
Numerous animal experiments and human observational studies supported that a higher intake of 
cholesterol can reduce the risk of developing PD. The reason for this may be the increased 
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cholesterol turnover in the brain, which promotes central nervous system repair processes thus 
reducing the risk of developing PD 24. 
Many studies – including our study – have found inverse causal relationship of cholesterol level 
and risk of PD, which cannot be explained by lifestyle and dietary habits of the population, thus 
this may be an element of the process of PD. The possible causal relationship explored in some 
studies suggests that certain chronic neurodegenerative disorders – such as PD – are associated 
with impaired cholesterol homeostasis 25. 
In case of males, our results correlated with the previous findings related to the protective effect 
of abnormal lipid levels: we found negative association between dyslipidemia as a comorbidity 
and a risk of PD. The effect of hypertension was controversial, and it was also different by gender 
similarly to the findings of National FINRISK Study 15; according to the multivariate analyses, 
hypertension in females is associated with a lower risk of PD, while in males no association has 
been found. 
The strength of the present study is that prior to this study, little research had been conducted about 
the association between PD and some vascular risk factors in Hungary.  
Our study also has at least three limitations. First, the onset of PD and vascular risk 
factors/comorbidity is not clear because of the retrospective type of the study. Second, all 
diagnoses (PD, diabetes, hypertension, and dyslipidemia) were determined by the ICD codes 
gained from the MedSolution program of the hospital. Third, we lacked information regarding 
medications taken (e.g., antihypertensive drugs, statins, antidiabetics). 
This retrospective case-control study showed considerable relationship between diabetes mellitus 
and PD. The association between dyslipidemia and hypertension seemed to be gender-dependent. 
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Further prospective studies are needed to confirm these findings and to characterize their role in 
the prevention or therapy of PD (e.g. assessment of hypertension, diabetes and dyslipidemia). 
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Table 1. Baseline characteristics of participants 
Characteristics Cases Controls P-value* 
Participants 620 679  
Age, years (mean±SD) 75.67±10.24 74.85±10.72 0.162 
Female gender 294 (47.2%) 306 (45.1%) 0.390 
Comorbidities    
Diabetes mellitus 222 (35.8%) 118 (17.4%) <0.001 
Dyslipidemia 160 (25.8%) 244 (35.9%) <0.001 
Hypertension 408 (65.8%) 458 (67.4%) 0.530 
*Results of chi-square test 
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Table 2. Univariate logistic regression models of vascular factors associated with Parkinson’s 
disease in the case-control study 
Parameters Univariate 
 Males Females Total 
 OR 
(95 % CI) 
P value OR 
(95 % CI) 
P value OR 
(95 % CI) 
P value 
Diabetes mellitus  <0.001  <0.001  <0.001 
Yes 2.45 
(1.74–3.45) 
 
2.97 
(2.01–4.40) 
 2.65 
(2.05–3.43) 
 
No 1.00  1.00  1.00  
Dyslipidemia  <0.001  0.048  <0.001 
Yes 0.54 
(0.38–0.75) 
 
0.71 
(0.51–0.99) 
 0.62 
(0.49–0.79) 
 
No 1.00  1.00  1.00  
Hypertension  0.809  0.194  0.530 
Yes 1.04 
(0.76–1.42) 
 
0.79 
(0.56–1.13) 
 0.92 
(0.74–1.17) 
 
No 1.00  1.00  1.00  
OR=odds ratio, CI=confidence interval 
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Table 3. Multivariate logistic regression models of vascular factors associated with Parkinson’s 
disease in the case-control study 
Parameters Multivariate* 
 Males Females Total 
 OR 
(95 % CI) 
P value OR 
(95 % CI) 
P value OR 
(95 % CI) 
P value 
Diabetes mellitus  <0.001  <0.001  <0.001 
Yes 2.72 
(1.90–3.89) 
 
3.24 
(2.16–4.84) 
 2.86 
(2.19–3.73) 
 
No 1.00  1.00    
Dyslipidemia  <0.001  0.050  <0.001 
Yes 0.48 
(0.33–0.69) 
 
0.70 
(0.50–1.00) 
 0.58 
(0.46–0.75) 
 
No 1.00  1.00    
Hypertension  0.773  0.039  0.101 
Yes 0.95 
(0.69–1.32) 
 
0.68 
(0.48–0.98) 
 0.82 
(0.64–1.04) 
 
No 1.00  1.00  1.00  
*Adjusted for age. 
OR=odds ratio, CI=confidence interval 
 
